The Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) a Liberia -U. S. research team, plans to launch a natural history study of Ebola survivors to better understand the after-effects of Ebola virus disease.
Four sites in Monrovia and locations in the United States may begin enrollment into this study in the coming months.
The study is pending regulatory review and approval, according to statement issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
NIAID conducts and supports research at NIH, throughout the United States, and worldwide, to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.
PREVAIL is currently conducting trials of two experimental Ebola vaccines in Liberia with more than 600 people in Liberia participating in the first stage and about 1,500 volunteers are expected to enroll in Phase Two.
The trial, which began on February 2, 2015 in Monrovia, is testing the safety and efficacy of the cAd3-EBOZ candidate vaccine co-developed by NIAID scientists and GlaxoSmithKline, and the VSV-ZEBOV candidate vaccine developed by the Public Health Agency of Canada and licensed to NewLink Genetics Corporation and Merck.